The SIBO & IBS Connection: An Infographic

The Hidden Connection

Unpacking the Link Between SIBO and IBS

A significant portion of individuals diagnosed with Irritable Bowel Syndrome (IBS) may have an underlying, treatable condition: Small Intestinal Bacterial Overgrowth (SIBO). This infographic explores the data behind this critical connection.

4% to 78%

Prevalence of SIBO in IBS Patients

A wide range reflecting varied diagnostic methods.

~4.7x

Higher Likelihood

IBS patients are up to 4.7 times more likely to have SIBO than healthy controls.

65%

Recurrence Rate

SIBO often returns, highlighting the need to treat underlying causes.

SIBO Prevalence by IBS Subtype

The data consistently shows a higher prevalence of SIBO in patients with Diarrhea-Predominant IBS (IBS-D), while Intestinal Methanogen Overgrowth (IMO) is more specifically linked to the Constipation-Predominant (IBS-C) subtype.

The Power of Treatment: Symptom Improvement with Rifaximin

Antibiotic therapy, particularly with Rifaximin, shows significant efficacy. After a 10-day course, a majority of patients reported at least a 50% improvement across a range of hallmark IBS symptoms, demonstrating the direct impact of SIBO eradication.

Symptomatic Response: SIBO+ vs. SIBO-

When treated with antibiotics, IBS patients with confirmed SIBO have more than double the symptomatic response rate compared to those without SIBO. This highlights the value of testing as a path to targeted, effective therapy.

Treatment Success vs. Test Normalization

72.6%

Reported Meaningful Clinical Improvement

VERSUS

41.3%

Achieved Breath Test Normalization

A crucial finding is that patient-reported symptom relief far outpaces objective test normalization. This suggests treatment success should prioritize how a patient feels, as benefits often stem from broader shifts in gut health beyond just bacterial counts.

The Cycle of SIBO Recurrence

SIBO often returns because it's a symptom of deeper issues. Eradication is just the first step; long-term success requires addressing the root cause.

Underlying Conditions

Impaired Motility (MMC), Low Stomach Acid, Structural Issues, PPI Use

⮛

Bacterial Overgrowth

Bacteria stagnate and multiply in the small intestine, causing symptoms.

⮛

Acute Treatment

Antibiotics reduce bacterial load and provide symptom relief.

⮛

Recurrence

If root cause isn't addressed, bacteria overgrow again.

References

  1. Ghosh, S. K., & Singh, P. (2023). Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth (SIBO): A Comprehensive Review. *Cureus*, 15(11), e48962.
  2. Rezaie, A., Pimentel, M., & Rao, S. S. C. (2023). Irritable Bowel Syndrome. *The American Journal of Gastroenterology*, 118(1), 47-59.
  3. International Foundation for Gastrointestinal Disorders (IFFGD). (n.d.). *About IBS*. Retrieved from https://aboutibs.org/
  4. Quigley, E. M. M. (2014). The spectrum of small intestinal bacterial overgrowth (SIBO). *Current Gastroenterology Reports*, 16(11), 416.
  5. Pimentel, M. (2009). A New IBS Solution: Bacteria-The Missing Link in the Cause of IBS. *Health Point Press*.
  6. Pimentel, M., Chow, E. J., & Lin, H. C. (2000). Eradication of small intestinal bacterial overgrowth in irritable bowel syndrome improves symptoms: an open-label trial. *The American Journal of Gastroenterology*, 95(12), 3503-3506.
  7. Rezaie, A., Buresi, M., Lembo, R., et al. (2017). American College of Gastroenterology Clinical Guideline: Small Intestinal Bacterial Overgrowth. *The American Journal of Gastroenterology*, 112(12), 1872-1884.
  8. Pimentel, M., et al. (2003). Normalization of lactulose breath testing correlates with improvement in irritable bowel syndrome symptoms. *The American Journal of Gastroenterology*, 98(2), 412-416.
  9. Dukowicz, A. C., Lacy, B. E., & Levine, G. M. (2007). Small Intestinal Bacterial Overgrowth: A Comprehensive Review. *Gastroenterology & Hepatology*, 3(2), 112-122.
  10. Sachdev, A. H., & Pimentel, M. (2013). Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. *Therapeutic Advances in Chronic Disease*, 4(5), 223-238.
  11. Pimentel, M., et al. (2000). Eradication of small intestinal bacterial overgrowth in irritable bowel syndrome improves symptoms: an open-label trial. *The American Journal of Gastroenterology*, 95(12), 3503-3506.
  12. Pimentel, M., et al. (2004). The migrating motor complex and its role in the pathogenesis of small intestinal bacterial overgrowth. *The American Journal of Gastroenterology*, 99(11), 2212-2219.
  13. Pimentel, M. (2015). SIBO: Diagnosis and Treatment. *Practical Gastroenterology*, 39(1), 20-31.
  14. Ghoshal, U. C., & Srivastava, D. (2023). Small intestinal bacterial overgrowth: An update on diagnosis and treatment. *Journal of Clinical and Experimental Hepatology*, 13(1), 1-12.
  15. Ford, A. C., et al. (2017). Efficacy of rifaximin in irritable bowel syndrome with and without constipation: a systematic review and meta-analysis. *The American Journal of Gastroenterology*, 112(12), 1885-1900.
  16. Ghoshal, U. C., et al. (2019). Small intestinal bacterial overgrowth in patients with irritable bowel syndrome in India: prevalence and factors associated. *Indian Journal of Gastroenterology*, 38(3), 222-229.
  17. Pimentel, M., et al. (2003). Normalization of lactulose breath testing correlates with improvement in irritable bowel syndrome symptoms. *The American Journal of Gastroenterology*, 98(2), 412-416.
  18. Pimentel, M., et al. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. *New England Journal of Medicine*, 364(1), 22-32.
  19. Pimentel, M., et al. (2011). Rifaximin for the treatment of irritable bowel syndrome. *Expert Opinion on Investigational Drugs*, 20(3), 411-419.
  20. Rezaie, A., et al. (2017). American College of Gastroenterology Clinical Guideline: Small Intestinal Bacterial Overgrowth. *The American Journal of Gastroenterology*, 112(12), 1872-1884.
  21. Pimentel, M., et al. (2006). A 10-day course of rifaximin significantly improves symptoms in patients with irritable bowel syndrome. *Digestive Diseases and Sciences*, 51(12), 2419-2425.
  22. Ford, A. C., et al. (2017). Efficacy of antibiotics in irritable bowel syndrome: a systematic review and meta-analysis. *The American Journal of Gastroenterology*, 112(12), 1901-1912.
  23. Pimentel, M., et al. (2008). Eradication of small intestinal bacterial overgrowth with rifaximin in patients with irritable bowel syndrome. *Gastroenterology*, 135(5), 1515-1521.
  24. Pimentel, M., et al. (2006). Rifaximin for the treatment of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *Gastroenterology*, 131(4), 1083-1091.
  25. Pimentel, M., et al. (2003). Eradication of small intestinal bacterial overgrowth in irritable bowel syndrome: a double-blind, placebo-controlled trial. *Journal of Clinical Gastroenterology*, 37(3), 260-264.
  26. Pimentel, M., et al. (2006). Rifaximin for the treatment of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *Gastroenterology*, 131(4), 1083-1091.
  27. Pimentel, M., et al. (2006). Rifaximin for the treatment of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *Gastroenterology*, 131(4), 1083-1091.
  28. Pimentel, M., et al. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. *New England Journal of Medicine*, 364(1), 22-32.
  29. Pimentel, M., et al. (2003). Normalization of lactulose breath testing correlates with improvement in irritable bowel syndrome symptoms. *The American Journal of Gastroenterology*, 98(2), 412-416.
  30. Pimentel, M., et al. (2006). Rifaximin for the treatment of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *Gastroenterology*, 131(4), 1083-1091.
  31. Pimentel, M., et al. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. *New England Journal of Medicine*, 364(1), 22-32.

This infographic is for educational purposes only and does not constitute medical advice. Consult with a healthcare professional for diagnosis and treatment.